• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Myocardial Ischemia - Pipeline Review, Q1 2011 - Product Image

Myocardial Ischemia - Pipeline Review, Q1 2011

  • Published: January 2011
  • Region: World
  • 28 Pages
  • Global Markets Direct

Myocardial Ischemia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Myocardial Ischemia - Pipeline Review, Q1 2011', provides an overview of the Myocardial Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myocardial Ischemia. 'Myocardial Ischemia - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Myocardial Ischemia.
- A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia Overview
Therapeutics Development
An Overview of Pipeline Products for Myocardial Ischemia
Myocardial Ischemia Therapeutics under Development by Companies
Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Myocardial Ischemia Therapeutics Development
Cardium Therapeutics, Inc.
CardioVascular BioTherapeutics, Inc.
Ark Therapeutics Group plc
Merck KGaA
RegeneRx Biopharmaceuticals, Inc.
Viromed Co., Ltd.
Universities/Institutes Involved in Myocardial Ischemia Therapeutics Development
Myocardial Ischemia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Generx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myocardial Ischemia - Featured News
Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Myocardial Ischemia, 2011
Products under Development for Myocardial Ischemia – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Cardium Therapeutics, Inc., 2011
CardioVascular BioTherapeutics, Inc., 2011
Ark Therapeutics Group plc, 2011
Merck KGaA, 2011
RegeneRx Biopharmaceuticals, Inc., 2011
Viromed Co., Ltd., 2011
Assessment by Monotherapy Products, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011

List of Figures
Number of Products under Development for Myocardial Ischemia, 2011
Products under Development for Myocardial Ischemia – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos